FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2170639393> ?p ?o ?g. }

• W2170639393 endingPage "1697" @default.
• W2170639393 startingPage "1691" @default.
• W2170639393 abstract "BackgroundThe purpose of this study was to determine in limited small-cell lung cancer if locoregional irradiation concurrently with induction chemotherapy with cisplatin and etoposide prolongs survival when cisplatin is given daily as a radiosensitiser.Patients and methodsTwo-hundred and four eligible patients were randomised between standard radiosensitised induction chemoradiotherapy (arm A) with cisplatin (90 mg/m2 day 1) plus etoposide and daily radiosensitised induction chemoradiotherapy (arm B) with cisplatin (6 mg/m2/day) plus etoposide. Chemotherapy and chest irradiation (39.90 Gy in 15 fractions >3 weeks) both started on day 1.ResultsThere was no difference in survival between both arms with respective median, 2 and 5 years of 15.5 months, 35% and 18% in arm A and 17.0 months, 38% and 21% in arm B (P = 0.50). Performance status and T status were identified as independent prognostic factors for survival. In terms of local control rate, there was a statistical trend in favour of arm A with 2% only local relapse versus 10% in arm B. Daily cisplatin radiosensitisation was associated with more oesophagitis and thrombopenia but less nephrotoxicity.ConclusionInduction chemoradiotherapy resulted in both arms in good long-term survival, comparable to the best reported results and without improvement by daily cisplatin administration." @default.
• W2170639393 created "2016-06-24" @default.
• W2170639393 creator A5002166354 @default.
• W2170639393 creator A5002311944 @default.
• W2170639393 creator A5012125051 @default.
• W2170639393 creator A5013413007 @default.
• W2170639393 creator A5026495132 @default.
• W2170639393 creator A5028608240 @default.
• W2170639393 creator A5029328492 @default.
• W2170639393 creator A5029441411 @default.
• W2170639393 creator A5034353453 @default.
• W2170639393 creator A5035783150 @default.
• W2170639393 creator A5043875611 @default.
• W2170639393 creator A5043934647 @default.
• W2170639393 creator A5057557133 @default.
• W2170639393 creator A5089982794 @default.
• W2170639393 date "2008-10-01" @default.
• W2170639393 modified "2023-10-16" @default.
• W2170639393 title "A phase III randomised study of concomitant induction radiochemotherapy testing two modalities of radiosensitisation by cisplatin (standard versus daily) for limited small-cell lung cancer" @default.
• W2170639393 cites W1876445714 @default.
• W2170639393 cites W1894342532 @default.
• W2170639393 cites W1905406155 @default.
• W2170639393 cites W1918962731 @default.
• W2170639393 cites W1973510243 @default.
• W2170639393 cites W2085757096 @default.
• W2170639393 cites W2096471429 @default.
• W2170639393 cites W2108113897 @default.
• W2170639393 cites W2122939592 @default.
• W2170639393 cites W2125430981 @default.
• W2170639393 cites W2127093828 @default.
• W2170639393 cites W2131664752 @default.
• W2170639393 cites W2132247116 @default.
• W2170639393 cites W2134855461 @default.
• W2170639393 cites W2141539943 @default.
• W2170639393 cites W2142764975 @default.
• W2170639393 cites W2150713507 @default.
• W2170639393 cites W2150878803 @default.
• W2170639393 cites W2160012348 @default.
• W2170639393 cites W2216166526 @default.
• W2170639393 cites W2268765260 @default.
• W2170639393 cites W2312703485 @default.
• W2170639393 cites W2323020638 @default.
• W2170639393 cites W2339444986 @default.
• W2170639393 cites W2341745217 @default.
• W2170639393 cites W4434567 @default.
• W2170639393 doi "https://doi.org/10.1093/annonc/mdn354" @default.
• W2170639393 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18504252" @default.
• W2170639393 hasPublicationYear "2008" @default.
• W2170639393 type Work @default.
• W2170639393 sameAs 2170639393 @default.
• W2170639393 citedByCount "24" @default.
• W2170639393 countsByYear W21706393932012 @default.
• W2170639393 countsByYear W21706393932013 @default.
• W2170639393 countsByYear W21706393932014 @default.
• W2170639393 countsByYear W21706393932016 @default.
• W2170639393 countsByYear W21706393932017 @default.
• W2170639393 countsByYear W21706393932018 @default.
• W2170639393 countsByYear W21706393932019 @default.
• W2170639393 countsByYear W21706393932020 @default.
• W2170639393 countsByYear W21706393932022 @default.
• W2170639393 countsByYear W21706393932023 @default.
• W2170639393 crossrefType "journal-article" @default.
• W2170639393 hasAuthorship W2170639393A5002166354 @default.
• W2170639393 hasAuthorship W2170639393A5002311944 @default.
• W2170639393 hasAuthorship W2170639393A5012125051 @default.
• W2170639393 hasAuthorship W2170639393A5013413007 @default.
• W2170639393 hasAuthorship W2170639393A5026495132 @default.
• W2170639393 hasAuthorship W2170639393A5028608240 @default.
• W2170639393 hasAuthorship W2170639393A5029328492 @default.
• W2170639393 hasAuthorship W2170639393A5029441411 @default.
• W2170639393 hasAuthorship W2170639393A5034353453 @default.
• W2170639393 hasAuthorship W2170639393A5035783150 @default.
• W2170639393 hasAuthorship W2170639393A5043875611 @default.
• W2170639393 hasAuthorship W2170639393A5043934647 @default.
• W2170639393 hasAuthorship W2170639393A5057557133 @default.
• W2170639393 hasAuthorship W2170639393A5089982794 @default.
• W2170639393 hasBestOaLocation W21706393931 @default.
• W2170639393 hasConcept C126322002 @default.
• W2170639393 hasConcept C126894567 @default.
• W2170639393 hasConcept C141071460 @default.
• W2170639393 hasConcept C143998085 @default.
• W2170639393 hasConcept C2776256026 @default.
• W2170639393 hasConcept C2776694085 @default.
• W2170639393 hasConcept C2776907518 @default.
• W2170639393 hasConcept C2778119113 @default.
• W2170639393 hasConcept C2778239845 @default.
• W2170639393 hasConcept C2778424827 @default.
• W2170639393 hasConcept C2779384505 @default.
• W2170639393 hasConcept C2780258809 @default.
• W2170639393 hasConcept C509974204 @default.
• W2170639393 hasConcept C71924100 @default.
• W2170639393 hasConceptScore W2170639393C126322002 @default.
• W2170639393 hasConceptScore W2170639393C126894567 @default.
• W2170639393 hasConceptScore W2170639393C141071460 @default.
• W2170639393 hasConceptScore W2170639393C143998085 @default.
• W2170639393 hasConceptScore W2170639393C2776256026 @default.
• W2170639393 hasConceptScore W2170639393C2776694085 @default.
• W2170639393 hasConceptScore W2170639393C2776907518 @default.

• next